

8 October 2020

Dr Na Ma
Company Editor-in-Chief
Editorial Office - World Journal of Hepatology
Baishideng Publishing Group Inc

Dear Dr Ma,

Re: Manuscript NO: 58668, Minireviews

Thank you for your consideration and preliminary acceptance of our manuscript. We have carefully considered the reviewers' insightful comments and have addressed the issues in tracked (attached) and clean versions of the revised manuscript. Please find our point-by-point responses below.

Reviewer #1:

1. Introduction - line 7-8, the peak age group affected is 45-64.... should be 45-62 years over 40% of people over the age of 60 affected...should be 60 years affected

Response: *This has been amended*

2. MAFLD and Trends in Liver Transplantation: the author should added the full name before abbreviation of UNOS/OPTN ; for Scientific Registry of Transplant Recipient (SRTR), the author should mention the full name first before using the abbreviation SRTR as well.

Response: *This has been amended in the text and abbreviations section*

3. de novo MALFD --> de novo should be in italics and be consistent with italics in all manuscript including the figure 1.

Response: *The figure and text have been updated*

4. As figure 1 the authors also mentioned about genetics, epigenetics, microbiome as factors influencing MAFLD and extra-hepatic malignancy in pre- and post-transplant issues -- the authors should explained the impact of these factors in the main manuscript as well.

Response: *We thank the reviewer for this helpful comment. Two new paragraphs (under the sections headings of pre-transplant assessment and de novo MAFLD after transplant) have been added to discuss genetics, epigenetics and microbiome. A new sub-section on malignancy has been added to the pre-transplant assessment section and an additional sentence at the end of the first paragraph under the post-transplant outcomes section.*

Reviewer #2:

We thank reviewer #2 for their favourable review.

Reviewer #3:

1. Risk of developing cancer in other organs in patients with MAFLD should be mentioned.

Response: *This has been addressed – see point 4 response to Reviewer #1.*

2. Some spelling mistakes need to be corrected.

Response: *We have re-checked and addressed spelling mistakes. Additionally, we have reverted to the*

US spellings of words such as etiology, glycemic, sarcopenia etc.

We hope our responses are adequate and look forward to the publication of our manuscript in *World Journal of Hepatology*. Please contact me if you have any concerns.

Kind regards,



Dr Avik Majumdar
Staff Specialist Transplant Hepatologist